Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04649983
Other study ID # PBC012
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date September 1, 2019
Est. completion date July 1, 2024

Study information

Verified date April 2023
Source Chongqing Precision Biotech Co., Ltd
Contact Zhi Yang, PhD
Phone 86-13206140093
Email yangzhi@precision-biotech.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted CAR-T cells therapy for patients with relapsed/refractory B Cell Leukemia and Lymphoma.


Description:

Although the anti-CD19 CAR-T cell therapies have gained significant results in patients with relapsed and refractory B-cell hematologic malignancies. There are patients who resisted anti-CD19 CAR-T cells or with CD19 negative relapse. To make further improvement, We launch such a clinical trial using CD19 and CD22 targeted CAR-T cells for patients with relapsed and refractory B Cell Leukemia and Lymphoma to evaluate the efficacy and safety of CD19 and CD22 targeted CAR-T cell therapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date July 1, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 2 Years to 75 Years
Eligibility Inclusion Criteria: 1. Signed written informed consent 2. Diagnose as Relapsed and Refractory B Cell Leukemia and Lymphoma, and meet one of the following conditions: 1. Failed to standard chemotherapy regimens; 2. Relapse after complete remission, high-risk and / or refractory patients ; 3. Relapse after hematopoietic stem cell transplantation; 3. For patients with Ph + ALL, the following conditions must be met: those who have received a standard induction chemotherapy regimen and who have not achieved complete remission after TKI treatment or have relapsed after remission (cannot tolerate TKI treatment or have contraindications to TKI treatment or the presence of TKI class) Except for drug resistant patients); 4. Evidence for cell membrane CD19 and CD22 expression; 5. All genders ,ages: 2 to 75 years; 6. The expect time of survive is above 3 months; 7. KPS>60; 8. No serious mental disorders ; 9. Left ventricular ejection fraction =50% 10. Sufficient hepatic function defined by ALT/AST=3 x ULN and bilirubin=2 x ULN; 11. Sufficient renal function defined by creatinine clearance=2 x ULN; 12. Sufficient pulmonary function defined by indoor oxygen saturation=92%; 13. With single or venous blood collection standards, and no other cell collection contraindications; 14. Ability and willingness to adhere to the study visit schedule and all protocol requirements. Exclusion Criteria: 1. Previous history of other malignancy; 2. Presence of uncontrolled active infection; 3. Evidence of disorder that need the treatment by glucocorticoids; 4. Active or chronic GVHD; 5. The patients treatment by inhibitor of T cell; 6. Pregnant or breasting-feeding women; 7. Any situation that investigators regard not suitable for attending in this study (e.g. HIV , HCVinfection or intravenous drug addiction) or may affect the data analysis.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
CD19 and CD22 targeted CAR-T cells
A single infusion of CD19 and CD22 CAR-T cells will be administered intravenously

Locations

Country Name City State
China 920th Hospital of Joint Logistics Support Force Kunming Yunnan

Sponsors (1)

Lead Sponsor Collaborator
Chongqing Precision Biotech Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse events that related to treatment Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0) 2 years
Primary The response rate of CD19 and CD22 CAR-T treatment in patients with relapse/refractory B Cell Leukemia and Lymphoma The response rate of CD19 and CD22 CAR-T treatment will be recorded and assessed according to the National Comprehensive Cancer Network Guideline 6 months
Secondary Rate of CD19 and CD22 CAR-T cells in bone marrow and peripheral blood In vivo (bone marrow and peripheral blood) rate of CD19 and CD22 CAR-T cells were determined by means of flow cytometry 2 years
Secondary Quantity of CD19 and CD22 CAR copies in bone marrow and peripheral blood In vivo (bone marrow and peripheral blood) quantity of CD19 and CD22 CAR copies were determined by means of qPCR 2 years
Secondary Cellular kinetics of CD19 and CD22 positive cells in Bone marrow In vivo (bone marrow) rate and quantity of CD19 and CD22 positive cells were determined by means of flow cytometry 1 years
Secondary Levels of Cytokines in Serum In vivo (Serum) quantity of cytokines(IL-6?IL-10?TNF-a?CRP) 3 months
Secondary Duration of Response (DOR) of CD19 and CD22 CAR-T treatment in patients with refractory/relapsed B Cell Leukemia and Lymphoma DOR will be assessed from the first assessment of CR/CRi to the first assessment of recurrence or progression of the disease or death from any cause (censored) 2 years
Secondary Progress-free survival(PFS) of CD19 and CD22 CAR-T treatment in patients with refractory/relapsed B Cell Leukemia and Lymphoma PFS will be assessed from the first CAR-T cell infusion to death from any cause or the first assessment of progression (censored) 2 years
Secondary Overall survival(OS) of CD19 and CD22 CAR-T treatment in patients with refractory/relapsed B Cell Leukemia and Lymphoma OS will be assessed from the first CAR-T cell infusion to death from any cause (censored) 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05540340 - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant Phase 1
Completed NCT03415399 - Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma Phase 1
Withdrawn NCT03605589 - Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma Phase 1
Recruiting NCT04807881 - Phase Ib Clinical Study of Keynatinib Phase 1
Completed NCT05510596 - Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome N/A
Not yet recruiting NCT06350994 - Early Assessment of Cardiac Function After Treatment With CAR-T Cells
Terminated NCT02670317 - Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients. Phase 2
Completed NCT00998946 - Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma Phase 2
Terminated NCT00768339 - A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas Phase 1/Phase 2
Withdrawn NCT00538096 - A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma Phase 1
Terminated NCT00521638 - Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma Phase 1
Completed NCT00379574 - Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL Phase 1/Phase 2
Completed NCT00156013 - Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL) Phase 1/Phase 2
Completed NCT00147121 - Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203) Phase 2/Phase 3
Recruiting NCT04594798 - A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL Phase 2
Recruiting NCT04161248 - Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Early Phase 1
Withdrawn NCT04052061 - QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma Phase 1
Recruiting NCT04884035 - Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma Phase 1
Not yet recruiting NCT05834426 - Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers
Recruiting NCT05376709 - A Mixed Methods Study of Nutrition Practice in Cancer Care on Non-Hodgkin Lymphoma Population N/A